Meanwhile, ALDH6A1 was identified as a potential molecular signature for hepatocellular carcinoma (28), prostate cancer (29), and muscle insulin resistance in type 2 diabetes mellitus (30). This evidence concerns the gene ALDH6A1 and prostate carcinoma.